Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular (CV) events and hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D). Using CV MRI (CMR) and 31P-MRS in a longitudinal cohort study, we aimed to investigate the effects of the s...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Sharmaine Thirunavukarasu, Nicholas Jex, Amrit Chowdhary, Imtiaz Ul Hassan, Sam Straw, Thomas P. Craven, Miroslawa Gorecka, David A. Broadbent, Peter Swoboda, Klaus K. Witte, Richard M. Cubbon, Hui Xue, Peter Kellman, John P. Greenwood, Sven Plein, Eylem Levelt
פורמט: Artigo
שפה:אנגלית
יצא לאור: 2021
גישה מקוונת:https://doi.org/10.2337/db21-0270
https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים

פריטים דומים